Technology

Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body

Published

3 hours ago

October 1, 2026

Fentanyl Phase 2 Trial met all endpoints; Phase 3 planned for H1 2027

CAMBRIDGE, Mass., Oct. 1, 2026 /PRNewswire/ — Clear Scientific, Inc. today announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates fentanyl, subsequently accelerating its removal from the body into urine. The results provide validation of CS-1103’s novel mechanism of action. The trial met all endpoints, with CS-1103 accelerating the removal of fentanyl in human subjects and showing a favorable safety profile.

Fentanyl Phase 2 Trial met all endpoints; Phase 3 planned for H1 2027

To reflect the real-world scenarios in which people overdose on fentanyl and are subsequently treated with naloxone, all participants received both fentanyl and naloxone, then followed by CS-1103 or placebo. CS-1103 accelerated fentanyl excretion into urine 25-fold vs control, significantly reducing fentanyl body burden. Critically, CS-1103 did not interfere with the action of naloxone. All results were consistent with non-clinical findings, which have also demonstrated that CS-1103 rapidly reverses respiratory depression caused by synthetic opioids.

The single-site, double-blind, randomized, inpatient pharmacokinetic and clearance study enrolled 16 healthy adults. A single intravenous dose of CS-1103 was well tolerated, with no serious adverse events reported. All 16 participants completed the study.

“Fentanyl in the body makes rescue and transition to treatment significantly more challenging, said Shekar Shetty, Chief Executive Officer of Clear Scientific. “By removing fentanyl from the plasma and brain rather than replacing it, as with receptor antagonists, CS-1103 could help prevent potentially fatal re-narcotization and reduce or eliminate precipitated withdrawal enabling faster, safer transitions to addiction treatment, such as buprenorphine and methadone. “

About CS-1103

CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. The Company is initially targeting methamphetamine, fentanyl and cocaine, which are present in close to 95% of all US drug related fatalities. Clear Scientific’s pipeline includes indications in central nervous system (CNS), metabolic diseases, amongst others.

About Clear Scientific

Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland.

Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body. Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals.

About the Crisis

In 2024, synthetic opioids were associated with approximately 1 million emergency department visits and more than 55,000 fatalities. These events place a significant burden on healthcare systems, costing hospitals more than $30 billion annually and contributing to overcrowded emergency departments and prolonged patient boarding.

While naloxone successfully reverses opioid-induced respiratory depression, it faces increasing treatment limitations because of the presence of fentanyl in the body:

re-narcotization, a dangerous situation in which the fentanyl poisoning lasts longer than the naloxone blockadepolydrug situations, in which naloxone is less effective when other drugs of abuse are present along with fentanyl (e.g., methamphetamine, xylazine, cocaine, etc.)precipitated withdrawal, a sudden, severe onset of withdrawal symptoms caused when a receptor antagonist rapidly displaces an opioid from its receptors, before natural withdrawal would have occurred, making transition to medications for opioid user disorder, including buprenorphine, difficult and potentially dangerous

According to the White House, the fentanyl-fueled opioid crisis cost the U.S. economy nearly $2.7 trillion in 2023 —impacting healthcare, criminal justice, and productivity in every community.

CS-1103 is investigational and has not been approved by any health authority. Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number UG3DA059286-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

View original content to download multimedia:https://www.prnewswire.com/news-releases/clear-scientific-reports-positive-phase-2-results-for-cs-1103-the-first-investigational-therapeutic-that-removes-fentanyl-from-the-body-302896178.html

SOURCE Clear Scientific, Inc.

Technology

BOSGAME Brings Everyday Computing Upgrades to Amazon Prime Big Deal Days 2026

Published

40 minutes ago

October 1, 2026

Selected Mini PCs will be available at 20% to 35% off for a limited time on October 6–7

NEW YORK, Oct. 1, 2026 /PRNewswire/ — BOSGAME, a technology-based electronic product brand, will participate in Amazon Prime Big Deal Days 2026, offering limited-time savings on selected Mini PCs from October 6-7. Starting at 12:00 a.m. PDT on October 6, shoppers can save 20‑35% on list prices on featured models, offering a timely opportunity to upgrade their everyday computing setup for less.

As computers take on more tasks at home, consumers may prioritize different needs depending on how and where they use their devices. From home-office productivity and online learning to web browsing and media consumption, a compact PC can provide a practical computing option while taking up minimal desk space.

During Prime Big Deal Days, BOSGAME will feature four Mini PCs with different configurations to suit a range of everyday needs and budgets.

BOSGAME E5: Powered by AMD Ryzen 5 5300U, the E5 handles everyday office work, web browsing and multitasking. Triple-display support and a compact, VESA-mountable design help maximize workspace in home offices or smaller desk setups.BOSGAME E5 Plus: Built for flexible home and office productivity, the E5 Plus combines AMD Ryzen 5 5400U performance with triple 4K display support. Upgradeable memory and expandable storage also leave room for evolving computing needs.BOSGAME E2 Plus: Designed for work, study and home use, the E2 Plus supports document editing, online meetings, learning and streaming. Its compact design and triple-display capability suit classrooms, home offices and other everyday spaces.BOSGAME E3 Neo: Powered by Intel N95, the E3 Neo offers a compact solution for essential home and office computing. Triple 4K display support and 2.5G LAN add flexibility for multi-screen setups and reliable wired connectivity.

The promotion runs through October 7, with savings of up to 35%, subject to product availability and Amazon’s promotional terms.

Whether upgrading a home-office setup, adding a computer for study, or choosing a compact device for browsing and entertainment, shoppers can explore BOSGAME’s featured Mini PCs during Amazon Prime Big Deal Days. For full promotion and product details, please visit the BOSGAME Amazon storefront at https://www.amazon.com/stores/BOSGAME/page/66639804-4D20-4901-A26F-0E6FE3715282.

View original content to download multimedia:https://www.prnewswire.com/news-releases/bosgame-brings-everyday-computing-upgrades-to-amazon-prime-big-deal-days-2026-302890863.html

SOURCE Bosgame

Technology

FEAR IS BIGGER THAN EVER… AND ZERO LATENCY VR HAS THE SCIENCE TO PROVE IT

Published

40 minutes ago

October 1, 2026

Ahead of Halloween, Zero Latency VR brought in “scientist of fear” Dr. Coltan Scrivner to explain why people can’t stop playing with the things that scare them

MELBOURNE, Australia, Oct. 1, 2026 /PRNewswire/ — Zero Latency VR, the world’s largest and most innovative immersive VR network, is celebrating a double Halloween anniversary: three years since the launch of Outbreak, its free-roam zombie survival shooter, and one year since the debut of Haunted, its immersive haunted house experience. Rather than mark the occasion alone, the company brought in an outside expert: Dr. Coltan Scrivner, a research scientist who studies why humans seek out frightening things for fun.

In three years, Outbreak has thrown wave after wave of the undead at guests across Zero Latency’s venues worldwide. In the year since, Haunted has barely let anyone make it through the lobby without a scream. Between the two, Halloween has become the company’s busiest and loudest season, leading Zero Latency to ask Scrivner a simple question: why do we pay money to be scared on purpose?

Scrivner is a research scientist at Arizona State University known for his work on morbid curiosity, horror, and what he calls “recreational fear”; the mixed feeling of fear and enjoyment that draws people to haunted houses, horror films, and survival games. He is the author of Morbidly Curious: A Scientist Explains Why We Can’t Look Away, and his research has been featured in The New York Times, CNN, The Economist, NPR and Scientific American.

“Humans are built to play with the things that frighten us,” said Scrivner. “It’s a great way for us to learn how to better regulate our fear and anxiety. One of the best ways to learn how you and your friends react in stressful situations is to simulate a stressful situation, and immersive VR is unmatched in its ability to safely invoke fear while maintaining a playful psychological frame.”

According to Scrivner, that’s exactly what sets free-roam VR apart from other horror formats. “The very best scary games blur the line between fiction and reality,” he said. “Immersive VR pushes that boundary and opens up a whole new way to play with fear. I have never experienced a horror game as immersive as Haunted or Outbreak, both of them were scarier, and more fun, than I could have imagined.”

“We’ve had over eleven years to perfect the jump scare, and it turns out you can’t fake it. The science backs it up,” said Tim Ruse, CEO of Zero Latency VR. “If you’re not leaving Outbreak with a slightly elevated heart rate, or leaving Haunted a little rattled, we haven’t done our job. It’s nice to finally have someone with a PhD confirm that’s a good thing.”

Zero Latency has two special Halloween double-features this spooky season; guests can experience Haunted and Undead Arena, the post-apocalyptic zombie shooter game show, or combine Outbreak with Outbreak 2: Mall Mayhem for a full hour of adrenaline-filled zombie survival that will truly get the blood pumping. Book now.

ABOUT ZERO LATENCY VR:

Zero Latency VR is the global pioneer in immersive entertainment, pushing the boundaries of what’s possible in location-based experiences. As the largest free-roam VR network on the planet, with 150+ cutting-edge venues across 34 countries, Zero Latency is where thrill-seekers come to live out their wildest fantasies.

SOCIAL MEDIA LINKS:

Instagram and TikTok: @zerolatencyvr

LinkedIn: Zero Latency VR

Press Contact:

Luke Mitchell

PR & Communications Manager

+61 (0) 413614412

luke.mitchell@zerolatencyvr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fear-is-bigger-than-ever-and-zero-latency-vr-has-the-science-to-prove-it-302895855.html

SOURCE Zero Latency VR

Technology

Fulton Financial Corporation Announces Dates for Third Quarter 2026 Earnings Release and Webcast

Published

40 minutes ago

October 1, 2026

LANCASTER, Pa., Oct. 1, 2026 /PRNewswire/ — Fulton Financial Corporation (“Fulton”) (Nasdaq: FULT) today announced that it will distribute its third quarter 2026 earnings release and accompanying charts on Wednesday, October 21, at approximately 4:30 p.m. Eastern Time.

Fulton will host a conference call with analysts on Thursday, October 22, at 10 a.m. Eastern Time. Curt Myers, Chairman, CEO and President, will host the call. He will be joined by Rick Kraemer, Senior Executive Vice President and CFO.

The link to the webcast of this call can be found at https://investor.fultonbank.com. Participants can also access the audio-only webcast at: https://edge.media-server.com/mmc/p/yj9w42yd.

Fulton, a more than $34 billion Lancaster, Pa.-based financial holding company, has more than 3,400 employees and operates more than 200 financial centers in Pennsylvania, New Jersey, Maryland, Delaware and Virginia through Fulton Bank, N.A.

Additional information on Fulton can be found at https://investor.fultonbank.com.

Media Contact: Rachel Sharkey (717) 291-2831
Investor Contact: Patrick Lafferty (717) 327-2556

View original content to download multimedia:https://www.prnewswire.com/news-releases/fulton-financial-corporation-announces-dates-for-third-quarter-2026-earnings-release-and-webcast-302896285.html

SOURCE Fulton Financial Corporation